InsiderDB

Lobbying disclosures · Lobbying report

BMY: third_quarter 2026 lobbying report

Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions H.R.7635, the 340B PATIENTS Act H.R.1492, Ensuring Pathways to Innovation Cures (EPIC) Act Implementation of Inflation Reduction Act of 2022 ORPHAN Cures Act MINI Act H.R.4299, the Protecting Patient Access to Cancer and Complex Therapies Act of 2025 H.R.5509, Safe Step Act Issues related to biosimilars reimbursement issues Clinical Trial Modernization Act Essential medicines/Buy American regarding all bio-pharmaceutical provisions Discussions regarding condification of MFN policies Fixed dose

Follow BMY
Became public
Oct 20, 2026, 4:49 PM EDT
Event / period date
Not stated
Collected
Nov 11, 2026, 7:37 PM EST

Why this is connected

Legal-name match: BRISTOL-MYERS SQUIBB COMPANY is BRISTOL MYERS SQUIBB CO (https://www.sec.gov/Archives/edgar/data/14272/), differing only in punctuation, "the" or suffix spelling (Corp/Corporation).

Reported lobbying amounts

Expenses: $3,050,000.00

These are different reporting measures. They are not added together or treated as spending on one particular bill.

Source evidence

Read the source excerpt or record
{"url":"https://lda.gov/api/v1/filings/2ba12235-d88d-4cb5-815c-20e5961d8c83/","filing_uuid":"2ba12235-d88d-4cb5-815c-20e5961d8c83","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/2ba12235-d88d-4cb5-815c-20e5961d8c83/print/","filing_document_content_type":"text/html","income":null,"expenses":"3050000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Rodger Currie","dt_posted":"2026-10-20T16:49:43-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"801 Pennsylvania Ave, NW, Suite 745","registrant_address_2":null,"registrant_different_address":true,"registrant_city":"WASHINGTON","registrant_state":"DC","registrant_zip":"20004","registrant":{"id":7053,"url":"https://lda.gov/api/v1/registrants/7053/","house_registrant_id":31580,"name":"BRISTOL-MYERS SQUIBB COMPANY","description":"Lobbying on biopharmaceutical issues.","address_1":"801 Pennsylvania Ave, NW, Suite 745","address_2":null,"address_3":null,"address_4":null,"city":"WASHINGTON","state":"DC","state_display":"District of Columbia","zip":"20004","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"LAURA DAVIS EIDSON","contact_telephone":"+1 727-519-5721","dt_updated":"2026-07-30T14:10:40.000859-04:00"},"client":{"id":109642,"url":"https://lda.gov/api/v1/clients/109642/","client_id":12,"name":"BRISTOL-MYERS SQUIBB COMPANY","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2013-05-21"},"lobbying_activities":[{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions H.R.7635, the 340B PATIENTS Act","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":150789,"prefix":null,"prefix_display":null,"first_name":"RODGER","nickname":null,"middle_name":null,"last_name":"CURRIE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":36053,"prefix":null,"prefix_display":null,"first_name":"LANE","nickname":null,"middle_name":null,"last_name":"PENRY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":92488,"prefix":null,"prefix_display":null,"first_name":"KATHRYN","nickname":null,"middle_name":null,"last_name":"NOVARIA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146913,"prefix":null,"prefix_display":null,"first_name":"SOFIA","nickname":null,"middle_name":null,"last_name":"FOX","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":76410,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":null,"last_name":"DEOUDES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152647,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"CALVO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146914,"prefix":null,"prefix_display":null,"first_name":"KIRBY","nickname":null,"middle_name":null,"last_name":"MILLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154633,"prefix":null,"prefix_display":null,"first_name":"STEVEN","nickname":null,"middle_name":null,"last_name":"TILTON","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"H.R.1492, Ensuring Pathways to Innovation Cures (EPIC) Act Implementation of Inflation Reduction Act of 2022 ORPHAN Cures Act MINI Act H.R.4299, the Protecting Patient Access to Cancer and Complex Therapies Act of 2025 H.R.5509, Safe Step Act Issues related to biosimilars reimbursement issues Clinical Trial Modernization Act Essential medicines/Buy American regarding all bio-pharmaceutical provisions Discussions regarding condification of MFN policies Fixed dose conbination drugs and general research and development Prescription Information Modernization Act of 2026 (PIMA)","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":100551,"prefix":null,"prefix_display":null,"first_name":"THOMAS","nickname":null,"middle_name":null,"last_name":"BRUNET","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":150789,"prefix":null,"prefix_display":null,"first_name":"RODGER","nickname":null,"middle_name":null,"last_name":"CURRIE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":36053,"prefix":null,"prefix_display":null,"first_name":"LANE","nickname":null,"middle_name":null,"last_name":"PENRY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146913,"prefix":null,"prefix_display":null,"first_name":"SOFIA","nickname":null,"middle_name":null,"last_name":"FOX","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146914,"prefix":null,"prefix_display":null,"first_name":"KIRBY","nickname":null,"middle_name":null,"last_name":"MILLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152647,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"CALVO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":76410,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":null,"last_name":"DEOUDES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":92488,"prefix":null,"prefix_display":null,"first_name":"KATHRYN","nickname":null,"middle_name":null,"last_name":"NOVARIA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":155678,"prefix":null,"prefix_display":null,"first_name":"NICOLE","nickname":null,"middle_name":null,"last_name":"L'ESPERANCE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154633,"prefix":null,"prefix_display":null,"first_name":"STEVEN","nickname":null,"middle_name":null,"last_name":"TILTON","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Proposed policies regarding corporate tax reform - regarding all bio-pharmaceutical related provisions Discussions regarding OECD implementation","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":76410,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":null,"last_name":"DEOUDES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":36053,"prefix":null,"prefix_display":null,"first_name":"LANE","nickname":null,"middle_name":null,"last_name":"PENRY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":150789,"prefix":null,"prefix_display":null,"first_name":"RODGER","nickname":null,"middle_name":null,"last_name":"CURRIE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152647,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"CALVO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":100551,"prefix":null,"prefix_display":null,"first_name":"THOMAS","nickname":null,"middle_name":null,"last_name":"BRUNET","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154633,"prefix":null,"prefix_display":null,"first_name":"STEVEN","nickname":null,"middle_name":null,"last_name":"TILTON","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"Intellectual Property Reform concerning bio-pharmaceutical industry","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":100551,"prefix":null,"prefix_display":null,"first_name":"THOMAS","nickname":null,"middle_name":null,"last_name":"BRUNET","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":150789,"prefix":null,"prefix_display":null,"first_name":"RODGER","nickname":null,"middle_name":null,"last_name":"CURRIE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":36053,"prefix":null,"prefix_display":null,"first_name":"LANE","nickname":null,"middle_name":null,"last_name":"PENRY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146913,"prefix":null,"prefix_display":null,"first_name":"SOFIA","nickname":null,"middle_name":null,"last_name":"FOX","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152647,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"CALVO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154633,"prefix":null,"prefix_display":null,"first_name":"STEVEN","nickname":null,"middle_name":null,"last_name":"TILTON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":155678,"prefix":null,"prefix_display":null,"first_name":"NICOLE","nickname":null,"middle_name":null,"last_name":"L'ESPERANCE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"International Reference Pricing/Most Favored Nation, including all bio-pharmaceutical issues Issues concerning competitive trade","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":76410,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":null,"last_name":"DEOUDES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146913,"prefix":null,"prefix_display":null,"first_name":"SOFIA","nickname":null,"middle_name":null,"last_name":"FOX","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146914,"prefix":null,"prefix_display":null,"first_name":"KIRBY","nickname":null,"middle_name":null,"last_name":"MILLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":150789,"prefix":null,"prefix_display":null,"first_name":"RODGER","nickname":null,"middle_name":null,"last_name":"CURRIE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152647,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"CALVO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":36053,"prefix":null,"prefix_display":null,"first_name":"LANE","nickname":null,"middle_name":null,"last_name":"PENRY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":100551,"prefix":null,"prefix_display":null,"first_name":"THOMAS","nickname":null,"middle_name":null,"last_name":"BRUNET","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154633,"prefix":null,"prefix_display":null,"first_name":"STEVEN","nickname":null,"middle_name":null,"last_name":"TILTON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":92488,"prefix":null,"prefix_display":null,"first_name":"KATHRYN","nickname":null,"middle_name":null,"last_name":"NOVARIA","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}

Congressional trading in BMY

These disclosures provide context. Their presence does not establish a link between a trader and the event.

Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.